Oncology and Solid Tumor Research
D3 Bio (Wuxi) Co. Ltd. focuses on clinical research in advanced solid tumors, with attention to cancers carrying a KRAS p.G12C mutation. Its trial activity is centered on adult oncology populations with molecularly defined disease.
- Advanced solid tumors
- KRAS p.G12C-mutant cancer
- Adult oncology
The sponsor’s research interest is concentrated on targeted cancer treatment for mutation-driven malignancies, including both single-agent and combination approaches within solid tumor care.
Targeted Therapy Development
The clinical program reflects an interest in precision oncology and molecularly targeted therapy for tumors defined by KRAS p.G12C alterations. The therapeutic focus is on agents designed to address a specific oncogenic driver.
- Precision oncology
- Molecularly targeted treatment
- KRAS pathway
Research activity in this area highlights interest in therapies aimed at oncogenic signaling and mutation-selective cancer treatment strategies.
Combination Anti-Cancer Therapy
D3 Bio also explores combination therapy in solid tumors, pairing its investigational oncology program with other anti-cancer medicines. This area of interest supports treatment strategies for difficult-to-treat metastatic or advanced malignancies.
- Combination oncology regimens
- Anti-cancer medicines
- Advanced malignancy
The sponsor’s trial portfolio includes both monotherapy and combination treatment settings in mutation-selected cancer populations.
Safety and Tolerability in Oncology
A key therapeutic interest is the evaluation of safety and tolerability in patients with advanced cancer. The sponsor’s clinical work is directed toward understanding how investigational oncology treatments are handled in adult subjects with KRAS-mutant tumors.
- Safety assessment
- Tolerability evaluation
- Adult subjects
This research area is closely tied to the clinical development of new cancer therapies for patients with limited treatment options.
